• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepanes Azepanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepanes

Professional Introduction to 4,4-dimethylazepane-1-sulfonyl chloride (CAS No. 1494928-34-5)

4,4-dimethylazepane-1-sulfonyl chloride, with the chemical identifier CAS No. 1494928-34-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the azepane class of heterocyclic compounds, characterized by a seven-membered ring containing two nitrogen atoms. The presence of sulfonyl chloride functionality at the 1-position of the azepane ring imparts unique reactivity, making it a valuable intermediate in the synthesis of various bioactive molecules.

The structure of 4,4-dimethylazepane-1-sulfonyl chloride features a highly symmetric arrangement, with two methyl groups at the 4-position and a sulfonyl chloride group at the 1-position. This structural motif contributes to its stability under standard conditions while also facilitating further chemical transformations. The compound is typically used as a building block in the synthesis of more complex molecules, particularly in the development of drugs targeting neurological and cardiovascular disorders.

In recent years, there has been growing interest in azepane derivatives due to their potential pharmacological properties. The dimethyl substitution at the 4-position enhances lipophilicity, which can improve membrane permeability and oral bioavailability—a critical factor in drug design. Furthermore, the sulfonyl chloride group serves as a versatile handle for further functionalization via nucleophilic substitution reactions, allowing chemists to introduce diverse side chains or linkages.

One of the most compelling applications of 4,4-dimethylazepane-1-sulfonyl chloride lies in its role as a precursor in the synthesis of GABA (gamma-aminobutyric acid) receptor modulators. GABA is an inhibitory neurotransmitter that plays a crucial role in regulating neuronal excitability. Modulators of GABA receptors have been extensively studied for their potential therapeutic effects in treating conditions such as anxiety, epilepsy, and insomnia. The azepane core mimics the natural binding site of GABA, while modifications introduced via sulfonyl chloride reactions can fine-tune receptor affinity and selectivity.

Recent advancements in medicinal chemistry have highlighted the utility of sulfonylated azepanes as scaffold compounds. A notable study published in *Journal of Medicinal Chemistry* demonstrated that derivatives of 4,4-dimethylazepane-1-sulfonyl chloride exhibit potent binding affinity for serotonin receptors (5-HT3). These findings open up new avenues for developing treatments against nausea and vomiting associated with chemotherapy and radiation therapy. The study employed high-throughput screening (HTS) combined with structure-activity relationship (SAR) analysis to optimize lead compounds derived from this scaffold.

The synthetic route to 4,4-dimethylazepane-1-sulfonyl chloride typically involves multi-step organic transformations starting from commercially available precursors such as 2-methylazepane or its derivatives. The introduction of the sulfonyl chloride group is achieved through chlorosulfonation followed by hydrolysis or direct sulfonylation using reagents like phosphorus pentachloride (PCl?) or chlorosulfonic acid (ClSO?H). The reaction conditions must be carefully controlled to avoid side products and ensure high yield and purity.

In terms of pharmacokinetic properties, early pharmacokinetic studies suggest that compounds derived from 4,4-dimethylazepane-1-sulfonyl chloride exhibit moderate solubility in water and good oral bioavailability. This profile makes them suitable for further development into clinical candidates. However, additional studies are needed to evaluate metabolic stability and potential drug-drug interactions before moving into human trials.

The demand for high-quality intermediates like CAS No. 1494928-34-5 continues to rise as pharmaceutical companies seek innovative solutions for drug discovery programs. Suppliers specializing in fine chemicals must adhere to stringent quality control measures to ensure consistency and reliability for researchers worldwide. Advances in synthetic methodologies have enabled scalable production processes that meet industry standards without compromising purity or yield.

Future research directions may explore modifications to the dimethylazepane core, such as introducing fluorine atoms or other heteroatoms to enhance metabolic stability or receptor selectivity. Additionally, computational modeling techniques could be employed to predict binding affinities and optimize lead structures before experimental synthesis begins—a strategy that aligns with modern drug discovery trends toward efficiency and sustainability.

In conclusion,4,4-dimethylazepane-1-sulfonyl chloride represents a promising intermediate with significant potential in pharmaceutical development. Its unique structural features make it an attractive scaffold for designing novel bioactive molecules targeting neurological disorders among others. As research progresses,CAS No. 1494928-34-5 will undoubtedly play an essential role in advancing therapeutic innovation across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)